September 6, 2019
September 6, 2019 – Takeda Pharmaceuticals has voluntarily recalled all doses of Natpara® (parathyroid hormone) for injection due to the potential for rubber particles to break off from the rubber septum of the Natpara cartridge.
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Health
September 6, 2019
September 6, 2019 – The U.S. FDA has approved a new indication for Ofev® (nintedanib), manufactured by Boehringer Ingelheim, to slow the rate of decline in pulmonary function in patients who have systemic-sclerosis-associated interstitial lung disease (SSc-ILD). It is the first drug to receive FDA-approval for this indication.
September 6, 2019
September 6, 2019 – In a brief statement, the U.S. FDA has again encouraged the public to take steps to prevent the measles, mumps, and rubella by following appropriate vaccination schedules for the MMR vaccine.
September 5, 2019
September 5, 2019 – The U.S. FDA has approved oral pellet dosage forms for Sovaldi® (sofosbuvir) and Harvoni® (ledipasvir/sofosbuvir), manufactured by Gilead. The FDA has also granted an extended pediatric indication to each product.
September 4, 2019
September 4, 2019 – The U.S. FDA has approved a Novitium Pharma’s generic version of Sobi’s Orfadin® (nitisinone) capsules. Nitisinone capsules are indicated for use in combination with dietary restriction of tyrosine and phenylalanine to treat adult and pediatric patients who have hereditary tyrosinemia type 1 (HT-1).
September 3, 2019
September 3, 2019 – Endo Pharmaceuticals has announced the launch of its authorized generic for Merck's Noxafil® (posaconazole) 100mg delayed-release tablets. The generic received FDA approval in August 2019, and is indicated to prevent invasive Aspergillus and Candida infections in patients who are at high risk
August 30, 2019
August 30, 2019 – Pacifico National, doing business as AmEx Pharmacy, has announced the voluntary recall of all lots of Bevacizumab 1.25mg/0.05ml 31g Injectable and all lots of Bevacizumab 2.5mg/0.1ml Norm-Ject TB Injectable that are within expiry to the healthcare provider level. The products have been recalled out of
August 29, 2019
August 29, 2019 – The U.S. FDA has granted tentative approval to Mylan’s generic for Eli Lilly’s Alimta® (pemetrexed injection). The product is indicated to treat of pleural mesothelioma and non-small cell lung cancer.